{"classes":[{"categories":[{"measurements":[{"comment":"Not calculated when N ≤ 2","groupId":"OG000","spread":"NA","value":"2250"},{"groupId":"OG001","spread":"96.1","value":"3440"},{"groupId":"OG002","spread":"35.8","value":"1660"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Cycle 1 day 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"87.7","value":"1830"},{"groupId":"OG002","spread":"12.4","value":"1900"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Cycle 2 day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Oprozomib plasma concentrations were determined using liquid chromatography with tandem mass spectrometry.\n\nThe area under the plasma concentration-time curve from time 0 to time infinity (AUCinf), estimated as the sum of AUClast and Clast/λz, where Clast is the last predicted concentration and λz is the first-order terminal rate constant estimated via linear regression of the terminal log-linear decay phase.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 2 or 4 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle.","id":"OG000","title":"Oprozomib 150 mg 5/14 + Pomalidomide + Dexamethasone"},{"description":"Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle.","id":"OG001","title":"Oprozomib 210 mg 2/7 + Pomalidomide + Dexamethasone"},{"description":"Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.","id":"OG002","title":"Oprozomib 240 mg 2/7 + Pomalidomide 4 mg + Dexamethasone"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants with adequate oprozomib plasma concentration-versus-time data to allow estimation of pharmacokinetic (PK) parameters. Treatment groups receiving the same dose of oprozomib were combined for PK analyses.","reportingStatus":"POSTED","timeFrame":"Cycle 1 day 1 at predose and 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours postdose. Cycle 2 day 1 at predose and 0.25, 0.5, 1, 2, 3, 4, and 6 hours postdose.","title":"Area Under the Plasma Concentration-time Curve From Time 0 to Time Infinity (AUCinf) of Oprozomib","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}